NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

NCT05394493

CompletedN/A

Sponsor: Pfizer

Conditions: Advanced Renal Cell Carcinoma

Interventions: avelumab, axitinib

Countries: United Kingdom

An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

* Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
* Patients with a documented diagnosis of aRCC.
* Patients aged ≥18 years old at the index event date.
* Patient initiated on treatment with avelumab in combination with axitinib ( ≥1 dose) on or after 1st August 2019.

Exclusion criteria

* Patients meeting any of the following criteria will not be included in the study:
* Patients who received avelumab in combination with axitinib as part of a clinical trial
* Patients initiated on avelumab in combination with axitinib less than 12 months from the end of data collection.
* Patients who are known to have opted out of participation in any research

Locations (1)

Sandwich, Kent, United Kingdom